Vol 11, No 4 (August 2022): Chinese Clinical Oncology

Review Article

Immunometabolism, a new therapeutic development for immunotherapies of high-grade gliomas: a narrative review
Janet Y. Wu, Alexander L. Ren, Michael Lim
Chinese Clinical Oncology
 2022;
11
(4)
:26
The challenging surgical management of hepatic epithelioid hemangioendothelioma: a narrative review
Francesco Giovanardi, Zoe Larghi Laureiro, Gerardina Anna Meo, Redan Hassan, Quirino Lai
Chinese Clinical Oncology
 2022;
11
(4)
:27
Non-colorectal non-neuroendocrine liver metastasis: a narrative review of surgical treatment
Celeste Del Basso, Sofia Usai, Giovanni Battista Levi Sandri
Chinese Clinical Oncology
 2022;
11
(4)
:28
A narrative review on the management of glioblastoma in China
Ming-Juan Zhao, Taojunjing Lu, Chao Ma, Ze-Fen Wang, Zhi-Qiang Li
Chinese Clinical Oncology
 2022;
11
(4)
:29
Measuring response to neoadjuvant therapy using biomarkers in pancreatic cancer: a narrative review
Catherine Valukas, Akhil Chawla
Chinese Clinical Oncology
 2022;
11
(4)
:30

Interviews with Outstanding Guest Editors1

Interview with Prof. Savio George Barreto: pancreatic cancer—an old problem needs a fresh perspective
Savio George Barreto, Yixuan Zeng, Lucine M. Gao
Chinese Clinical Oncology
 2022;
11
(4)
:32
Interview with Prof. Rimas V. Lukas: discussion with an academic neuro-oncologist
Rimas V. Lukas, Yixuan Zeng, Lucine M. Gao
Chinese Clinical Oncology
 2022;
11
(4)
:33

Disclosure:

1. The series “Interviews with Outstanding Guest Editors” was commissioned by the editorial office, Chinese Clinical Oncology without any funding or sponsorship.